Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma
- PMID: 15078633
- DOI: 10.1245/ASO.2004.04.032
Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma
Abstract
Background: The influence of isolated limb perfusion (ILP) on the limb recurrence-free interval (LRFI) and the number of lesions per recurrence was studied for patients with frequently recurring regional in-transit metastases previously managed by excisional surgery.
Methods: All 43 patients who had their first ILP for a third or further limb recurrence were selected from our computer database of 451 patients who underwent therapeutic ILP for recurrent extremity melanoma in our centers. Eighteen patients had resectable and 25 had locally unresectable lesions at the time of ILP. The patients had a total of 269 intervals between treatment of their primary melanoma and last recurrence or last follow-up. Median follow-up was 35 months (interquartile range, 14-64 months).
Results: The median LRFI decreases over time from primary melanoma to the third or further recurrence for which ILP was performed (P < 0.001). The median LRFI is 4.7 times longer (95% confidence interval [CI], 2.8-7.9; P < 0.001) after ILP in comparison with the last interval before ILP. Patients with resectable lesions have a median LRFI that is 5.9 times longer (95% CI, 2.7-13; P < 0.001). In all patients, the number of lesions increases by 22% per recurrence number (95% CI, 10%-35%; P = 0.02). At the same recurrence number, patients before ILP have a 2.6-fold higher (95% CI, 1.6-4.5) mean number of lesions than do patients after ILP (P < 0.001).
Conclusions: ILP lengthens the LRFI and decreases the number of lesions per recurrence significantly in patients with repeatedly recurrent limb melanoma. Therefore, ILP could be a valuable adjunct to excisional surgery for in-transit metastases in these patients whose LRFIs tend to shorten over time.
Comment in
-
Where are we going with regional therapy for melanoma?Ann Surg Oncol. 2004 May;11(5):455-7. doi: 10.1245/ASO.2004.03.911. Epub 2004 Apr 12. Ann Surg Oncol. 2004. PMID: 15078631 No abstract available.
Similar articles
-
Isolated limb perfusion for unresectable melanoma of the extremities.Arch Surg. 2004 Nov;139(11):1237-42. doi: 10.1001/archsurg.139.11.1237. Arch Surg. 2004. PMID: 15545572
-
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.J Am Coll Surg. 1996 Jun;182(6):467-72. J Am Coll Surg. 1996. PMID: 8646345
-
Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.Eur J Surg Oncol. 2006 Apr;32(3):318-24. doi: 10.1016/j.ejso.2005.10.009. Epub 2006 Jan 18. Eur J Surg Oncol. 2006. PMID: 16412605
-
Isolated limb perfusion in regional melanoma.Surg Oncol Clin N Am. 2006 Apr;15(2):373-84. doi: 10.1016/j.soc.2005.12.004. Surg Oncol Clin N Am. 2006. PMID: 16632221 Review.
-
Isolated limb perfusion for melanoma.Surg Oncol Clin N Am. 2008 Oct;17(4):785-94, viii-ix. doi: 10.1016/j.soc.2008.04.005. Surg Oncol Clin N Am. 2008. PMID: 18722918 Review.
Cited by
-
Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature.Cancers (Basel). 2021 Oct 31;13(21):5485. doi: 10.3390/cancers13215485. Cancers (Basel). 2021. PMID: 34771649 Free PMC article. Review.
-
Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety.Oncologist. 2010;15(4):416-27. doi: 10.1634/theoncologist.2009-0325. Epub 2010 Mar 26. Oncologist. 2010. PMID: 20348274 Free PMC article.
-
Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology.Ann Surg. 2007 Apr;245(4):591-6. doi: 10.1097/01.sla.0000251746.02764.fc. Ann Surg. 2007. PMID: 17414608 Free PMC article.
-
Toxicity and morbility after isolated lower limb perfusion in 242 chemo-hyperthermal treatments for cutaneous melanoma: the experience of the Tuscan Reference Centre.J Exp Clin Cancer Res. 2008 Nov 12;27(1):67. doi: 10.1186/1756-9966-27-67. J Exp Clin Cancer Res. 2008. PMID: 19014470 Free PMC article.
-
Xeroderma Pigmentosum: A Genetic Condition Skin Cancer Correlated-A Systematic Review.Biomed Res Int. 2022 Jul 18;2022:8549532. doi: 10.1155/2022/8549532. eCollection 2022. Biomed Res Int. 2022. PMID: 35898688 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical